Our Top 5 Microcap Stocks
Microcap stocks tend to be an under-researched area… Which increases the odds of discovering attractive investment opportunities.

Just like these 5 which appear to be in an excellent position to see a surge in share price.
>>> See All 5 Here
pixel
Paul Blanchfield net worth and biography

Paul Blanchfield Biography and Net Worth

Insider of Lantheus
Paul Blanchfield serves as our Chief Commercial Officer, having joined Lantheus in January 2020.  Prior to Lantheus, Mr. Blanchfield worked at Takeda Pharmaceutical Co. where he served as the Head of the U.S. Immunology Business Unit and managed a multi-billion dollar P&L covering multiple rare diseases products. Prior to his time at Takeda, Mr. Blanchfield served in several different roles at Shire Plc across almost 6 years, including as the Head of U.S. Immunology, General Manager of Nordic-Baltics, Head of Corporate Strategy, and Chief of Staff to the CEO. In his time at Shire, Mr. Blanchfield launched multiple products, worked across nine different countries, oversaw a restructuring to increase commercial focus and reduce costs, and led efforts in M&A, corporate defense, integration, and long-term corporate and portfolio strategy. Prior to his time at Shire, Mr. Blanchfield worked at McKinsey & Company for 5 years, where he focused on health care, marketing, and sales. Mr. Blanchfield earned an MBA / MA in Education from Stanford University and an AB in Economics from Duke University.

What is Paul Blanchfield's net worth?

The estimated net worth of Paul Blanchfield is at least $4.53 million as of November 17th, 2022. Mr. Blanchfield owns 73,968 shares of Lantheus stock worth more than $4,530,540 as of December 1st. This net worth estimate does not reflect any other investments that Mr. Blanchfield may own. Additionally, Mr. Blanchfield receives an annual salary of $734,540.00 as Insider at Lantheus. Learn More about Paul Blanchfield's net worth.

How old is Paul Blanchfield?

Mr. Blanchfield is currently 41 years old. There are 6 older executives and no younger executives at Lantheus. The oldest executive at Lantheus is Ms. Mary Anne Heino, CEO, Pres & Director, who is 62 years old. Learn More on Paul Blanchfield's age.

What is Paul Blanchfield's salary?

As the Insider of Lantheus Holdings, Inc., Mr. Blanchfield earns $734,540.00 per year. There are 2 executives that earn more than Mr. Blanchfield. The highest earning executive at Lantheus is Ms. Mary Anne Heino, CEO, Pres & Director, who commands a salary of $2,150,000.00 per year. Learn More on Paul Blanchfield's salary.

How do I contact Paul Blanchfield?

The corporate mailing address for Mr. Blanchfield and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected] Learn More on Paul Blanchfield's contact information.

Has Paul Blanchfield been buying or selling shares of Lantheus?

During the past quarter, Paul Blanchfield has sold $133,249.28 in shares of Lantheus stock. Most recently, Paul Blanchfield sold 2,432 shares of the business's stock in a transaction on Thursday, November 17th. The shares were sold at an average price of $54.79, for a transaction totalling $133,249.28. Following the completion of the sale, the chief operating officer now directly owns 73,968 shares of the company's stock, valued at $4,052,706.72. Learn More on Paul Blanchfield's trading history.

Who are Lantheus' active insiders?

Lantheus' insider roster includes Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.

Are insiders buying or selling shares of Lantheus?

During the last year, insiders at the medical equipment provider sold shares 31 times. They sold a total of 216,316 shares worth more than $13,098,685.15. The most recent insider tranaction occured on November, 17th when COO Paul Blanchfield sold 2,432 shares worth more than $133,249.28. Insiders at Lantheus own 1.6 % of the company. Learn More about insider trades at Lantheus.

Information on this page was last updated on 11/17/2022.

Paul Blanchfield Insider Trading History at Lantheus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2022Sell2,432$54.79$133,249.2873,968View SEC Filing Icon  
8/18/2022Sell1,500$83.39$125,085.0076,143View SEC Filing Icon  
3/4/2022Sell3,914$49.98$195,621.72View SEC Filing Icon  
3/4/2021Sell4,061$18.40$74,722.40View SEC Filing Icon  
See Full Table

Paul Blanchfield Buying and Selling Activity at Lantheus

This chart shows Paul Blanchfield's buying and selling at Lantheus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lantheus Company Overview

Lantheus logo
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Read More

Today's Range

Now: $61.25
Low: $60.27
High: $63.09

50 Day Range

MA: $65.89
Low: $55.11
High: $77.67

2 Week Range

Now: $61.25
Low: $23.51
High: $87.47

Volume

640,227 shs

Average Volume

1,159,568 shs

Market Capitalization

$4.22 billion

P/E Ratio

41.11

Dividend Yield

N/A

Beta

0.79
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
pixel